¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"systemic inflammatory response syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® testicular feminization syndrome ÇÑ±Û °íȯ¿©¼ºÈ­ÁõÈıº
¼³¸í   
  ÀÌÂ÷¼ºÀåÀ» Æ÷ÇÔÇÏ¿©, ¿Ü¼º±âÀÇ ¹ßÀ°Àº ¿©¼ºÀÌÁö¸¸ °íȯÀÌ Á¸ÀçÇϰí, Àڱðú ÀڱðüÀÌ °áÇ̵Ǿî Àִ ³²¼º °ÅÁþ³²³àÇѸöÁõÀÇ ±Ø´ÜÀû ÇüÅÂÀÌ´Ù. À̰ÍÀº Å×½ºÅ佺Å×·ÐÀÇ ÀÛ¿ë¿¡ ´ëÇÑ ¸»´Ü±â°üÀÇ ÀúÇ׿¡ ±âÀÎÇÑ´Ù.
  
  
¿µ¹® irritable bowel syndrome ÇÑ±Û °ú¹Î¼º´ëÀåÁõÈıº
¼³¸í   
  ¹èº¯Àå¾Ö, º¹Åë, º¹ºÎÆØ¸¸ µîÀÇ Áõ»óÀÌ ÀÖÀ¸³ª ±âÁúÀûÀΠº´º¯ÀÌ ¾øÀ½ÀÌ È®ÀεȠ¿¹¸¦ ÃѸÁ¶óÇÑ ÀÓ»ó ÁõÈıºÀÌ´Ù. °¡Àå ÈçÇÑ ¼ÒÈ­±â ÁúȯÀ̸ç(Àü¼ÒÈ­±â È¯ÀÚÀÇ 70~80%) °¡Àå ÈçÇÑ Áúº´(Àüü Àα¸ÀÇ ¾à 20%)ÀÌ´Ù. ¿©¼ºÀÌ ³²¼º¿¡ ºñÇØ 2¹è Á¤µµ ¸¹ÀÌ ¹ß»ýÇϸç 30´ë ¹× 40´ë¿¡¼­ È£¹ßÇÏ°í ¼±Áø °ø¾÷±¹¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. Áø´ÜÀ» À§Çؼ­´Â º´·Â Ã»Ãë°¡ °¡Àå Áß¿äÇ졒ʡ¢Á¾ °Ë»ç·Î¼­ ±âÁúº´À» Á¦¿ÜÇØ¾ß ÇÑ´Ù. Ä¡·á·Î´Â ¾ÈÁ¤¿ä¹ý(Á¤½Å°úÀû ¸é´ã ¹× ½É¸®¿ä¹ý, ½Å°æ¾ÈÁ¤Á¦), ½Ä»ç¿ä¹ý(°í¼¶À¯Áú À½½Ä ¼·Ãë, Àڱؼº À½½Ä ÇÇÇϱâ), ¾à¹° ¿ä¹ý(âÀÚ°æ·Ã ÁøÁ¤Á¦, º¯ºñ ¿ÏÈ­Á¦, Áö»çÁ¦) µîÀ» »ç¿ëÇÑ´Ù.
¿µ¹® withdrawal syndrome ÇÑ±Û ±Ý´ÜÁõÈıÙ
¼³¸í   
  ¾ËÄÚ¿Ã, ¸¶¾à, ¹ÙºñÅõ¸£»ê°è ÃÖ¸é¾à µîÀÇ ¾à¹°À» Àå±â°£ º¹¿ëÇÏ¿© ¾à¹°ÀÌ ¾øÀ̴ °ßµô ¼ö ¾ø°ÔµÈ µÚ, ±× ¾à¹°À» ÁßÁöÇÑ °æ¿ì¿¡ ³ªÅ¸³ª´Â, °íÅëÀÌ ¼ö¹ÝµÇ´Â ½ÅüÀû Áõ»óÀ» ¸»ÇÑ´Ù. ¿¬¼Ó º¹¿ëÀÇ ±â°£¿¡ µû¶ó Áõ»óÀÌ ¹«°Å¿öÁø´Ù. Åë»óÀûÀ¸·Î ±¸Åä, ¼³»ç, Ç÷¾Ð»ó½Â, ºü¸¥¸Æ, ¶¡³², È¥¼ö µîÀÇ Áõ»óÀÌ ³ªÅ¸³­´Ù.
  
  
¿µ¹® organic brain syndrome ÇÑ±Û ±âÁúÀû ³úÁõÈıº
¼³¸í   
  ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇϴ ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇϸ頾 ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö Àִٴ ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀΠÀ̻󿡠ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ È¯ÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹­¾î¼­ ¸»ÇÑ´Ù. À̻󿡠ÀÇÇØ ½Å°æÇÐÀûÀΠÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» È¾¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀΠ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼­¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Æ¯Â¡ÀûÀΠÁõ»óÀº ¸ÕÀú, ÀǽÄÀǠȥŹÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇѴٴ °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀΠÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼­ ¸»À» È¾¼³¼ö¼³ÇÑ´Ù¸é, À̴ ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù.
¿µ¹® Down syndrome ÇÑ±Û ´Ù¿îÁõÈıº
¼³¸í   
  »ç¶÷ÀÇ 46°³ ¿°»öü Áß Á¦ 21¹ø ¿°»öüÀÇ ¼ö°¡ 1°³ ´õ ¸¹¾ÆÁö¹Ç·Î½á ³ªÅ¸³ª´Â º´ÀÌ´Ù. È¯ÀÚÀÇ »ý±è»õ°¡ ¸¶Ä¡ ¸ù°í »ç¶÷°ú ´à¾Ò´Ù ÇÏ¿© ÀÏ¸í ¸ù°íÁõ(mongolism)À̶ó°í ÇÏ¿´À¸³ª À߸øµÈ À̸§ÀÌ´Ù. ÀÌ º´Àº ¹Ýµå½Ã 21¹ø ¿°»öü°¡ 3°³°¡ µÇ´Â °æ¿ìÀ̿ܿ¡µµ 21¹ø ¿°»öüÀÇ ÀϺκÐÀÌ ´Ù¸¥ ¿°»öüÀÇ ÀϺκаú ±³È¯ÀÌ µÇ´Â translocationÇü µîÀÇ ´Ù¸¥ ¿°»öüÀ̻󿡼­µµ º¼ ¼ö°¡ ÀÖ´Ù. ¹ß»ý ºóµµ´Â Ãâ»ý¾Æ 700~1000¸íÁß 1¸í ²Ã·Î ³ªÅ¸³ª¸ç, ¿°»öü À̻󺴠Áß¿¡ °¡Àå ¸¹Àº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ º´ÀÇ ¹ß»ýºóµµ´Â »ê¸ðÀÇ Ãâ»ê¿¬·É°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ¾î, 35¼¼ ÀÌÈİ¡ µÇ¸é ±âÇÏ ±Þ¼öÀûÀ¸·Î ÀÌ ÁúȯÀÚÀÇ Ãâ»ê¼ö°¡ Áõ°¡ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ Áúȯ¿¡ À־ ¾à 3ºÐÀÇ 1Àº ¸ðÄ£ÀÇ Ãâ»ê¿¬·É¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ³ª¸ÓÁö ¾à 3ºÐÀÇ 2´Â ¸ðÄ£ÀÇ ¿¬·É°ú Á÷Á¢ °ü·ÃÀÌ Àִ °ÍÀ¸·Î º¸°í ÀÖ´Ù. Áø´ÜÀº Æ¯Â¡ÀûÀΠ»ý±è»õ, Áï ¸ù°í »ç¶÷°°ÀÌ ´«²¿¸®°¡ À§·Î Ä¡ÄÑÁ® ÀÖ°í ´«°ÅÇ®ÀÌ µÎ²¨¿ì¸ç ÄàµîÀÌ ³·Àº Æ¯Â¡ÀûÀΠ¾ó±¼ ¸ð½À, ¶ÇÇÑ ±ÙÀ°ÀÇ ±äÀåµµ°¡ ÀúÇϵǰí Á¥À» ºü´Â Èû°ú ¿ïÀ½ ¼Ò¸®°¡ ¾àÇϸ砼չٴÚÀÇ Á¿츦 °¡¸£´Â ÇÑÁÙÀÇ ¼Õ±Ý(¿ø¼þÀ̿͠°°Àº ÇüÅÂÀÌ´Ù) µîÀǠƯ¡ÀûÀΠ¼Ò°ß¿¡ ÀÇÇØ º¸Á¶Áø´ÜÀ» Çϰí ÃÖÁ¾ÀûÀ¸·Î ¿°»öü ºÐ¼®¿¡ ÀÇÇØ È®ÁøÀ» ÇÑ´Ù. ÀÌ ´Ù¿îÁõÈıºÀǠȯÀڴ ´ë°³ Áö´ÉÀÌ ÀúÇϵǾî ÀÖ°í, ¿©·¯ °¡Áö Á¾·ùÀÇ ¼±Ãµ¼º ½ÉÀå±âÇüÀ» ¸¹ÀÌ µ¿¹ÝÇϰí ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • portal-systemic encephalopathy
    ¹®¸ÆÀü½Å¼øÈ¯(¼º)³úº´(Áõ)
  • progressive systemic sclerosis
    ÁøÇàÀü½Å°æÈ­Áõ
  • systemic
    1. Àü½Å¼º- 2. ü°èÀû
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • systemic death
    Àü½Å»ç¸Á
  • systemic disease
    Àü½Åº´
  • systemic embolism
    Àü½Å»öÀüÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic lesion
    °èÅ뺴ÅÍ
  • systemic lupus erythematosus
    Àü½ÅÈ«¹Ý·çǪ½º
  • systemic mastocytosis
    Àü½Åºñ¸¸¼¼Æ÷Áõ
  • systemic nodular panniculitis
    Àü½Å°áÀýÁö¹æÃþ¿°
  • systemic reaction
    Àü½Å¹ÝÀÀ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • systemic infection
    Àü½Å°¨¿°
  • systemic erythematosus lupus
    Àü½ÅÈ«¹Ý·çǪ½º
  • response
    ¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • late asthmatic response
    ¸¸±âõ½Ä¹ÝÀÀ, Èıâõ½Ä¹ÝÀÀ
  • response rate
    ¹ÝÀÀ·ü
  • startle response
    ³î¶÷¹ÝÀÀ
  • systemic reaction
    Àü½Å¹ÝÀÀ
  • withdrawal response
    ±Ý´Ü¹ÝÀÀ
  • systemic sclerosis
    Àü½Å°æÈ­Áõ
  • systemic treatment
    Àü½ÅÄ¡·á
  • systemic therapy
    Àü½Å¿ä¹ý
  • acquired immunodeficiency syndrome
    (¢¡AIDS) ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • syndrome of inappropriate antidiuretic hormone
    Ç×ÀÌ´¢È£¸£¸óºÎÀûÀýºÐºñÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic arachnidism
    Àü½Å°Å¹Ìµ¶Áõ
  • bullous systemic l. erythematosusv lupus
    ¹°ÁýÀü½ÅÈ«¹Ý·çÇÁ½º
  • systemic circulation
    ¿Â¸ö¼øÈ¯, ü¼øÈ¯
  • diffuse systemic sclerosis
    ±¤¹üÀ§Àü½Å°æÈ­Áõ
  • systemic death
    Àü½Å»ç
  • systemic disease
    Àü½Åº´
  • portal-systemic encephalopathy
    ¹®¸ÆÀü½Å¼øÈ¯³úº´Áõ
  • systemic embolism
    Àü½Å»öÀüÁõ
  • idiopathic systemic fibrosis
    Ư¹ßÀü½Å¼¶À¯Áõ
  • infantile systemic hyalinosis
    À¯¾ÆÀü½ÅÀ¯¸®ÁúÁõ
  • systemic hypotension
    Àü½ÅÀúÇ÷¾Ð
  • systemic infection
    Àü½Å°¨¿°
  • systemic lesion
    °èÅ뺴ÅÍ
  • systemic l. erythematosus lupus
    Àü½ÅÈ«¹Ý·çǪ½º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • porto-systemic shunt
    ¹®¸ÆÃ¼´Ü¶ô(Ó­Õ©)<--¼ÇÆ®>
  • primary systemic amyloidosis
    ¿ø¹ß¼º Àü½Å À¯ÀüºÐÁõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å °æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇà(¼º) Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å°æÈ­Áõ
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõ îñãóàõ Ìãûùñø)
  • progressive systemic sclerosis
    ÁøÇ༺ Àü½Å¼º °æÈ­Áõ(òäú¼àõîñãóàõÌãûùñø).
  • reactive systemic amyloidosis
    ¹ÝÀÀ¼º Àü½Å À¯ÀüºÐÁõ
  • BERA =Brainstem Evoked Response Audiometry
    ³ú°£À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • Fast response
    ±Þ¼Ó(ÐááÜ)¹ÝÀÀ(Úãëë)
  • Lewis triple response
    ·çÀ̽º »ïÁß ¹ÝÀÀ
  • MAC-BAR(minimum alveolar concentration-blockade of autonomic response)
    ÀÚÀ²½Å°æ¾ïÁ¦ ÃÖ¼ÒÆóÆ÷³»³óµµ
  • allergic response
    ¾Ë·¹¸£±â¹ÝÀÀ, °ú¹Î¹ÝÀÀ
  • analytical response detection
    ºÐ¼®¹ÝÀÀ°¨Áö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inflammatory linear verrucous epidermal nevus (ILVEN)
    ¿°Áõ¼º ¼±»ó »ç¸¶±Í¾ç Ç¥ÇǸð¹Ý
  • inflammatory pain
    ¿°Áõ¼º µ¿Åë.
  • inflammatory pseudotumor
    ¿°Áõ°¡¼ºÁ¾¾ç
  • inflammatory pseudotumor
    ¿°Áõ¼º °¡Á¾¾ç.(¡­ Ê£ðþåË)
  • inflammatory tissue reaction
    ¿°Áõ¼º Á¶Á÷¹ÝÀÀ
  • inflammatory trismus
    ¿°Áõ¼º °³±¸Àå¾Ö.
  • nonsteroidal anti-inflammatory drug
    ºñ½ºÅ×·ÎÀ̵强 Ç׿°Áõ¾à
  • nonsteroidal anti-inflammatory drug
    ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°Á¦
  • pelvic inflammatory disease
    °ñ¹Ý¿°Áõ¼º Áúȯ.
  • pelvic inflammatory disease
    °ñ¹Ý¿°Áúȯ(ÍéÚïæúòðü´)
  • pelvic inflammatory disease(PID)
    °ñ¹Ý³»°¨¿°
  • acute systemic lupus erythematosus = ASLE
    ±Þ¼º Àü½Å¼º È«¹Ý¼º ³¶Ã¢(¡­îïãóàõûõÚèàõÕÉóê)
  • acute systemic lupus erythematosus =ASLE
    ±Þ¼º Àü½Å¼º È«¹Ý¼º ³¶Ã¢(¡­îïãóàõûõÚèàõÕÉóê).
  • anomalies of systemic venous return
    ´ëÁ¤¸ÆÈ¯·ù(ÓÞð¡Øæü½êü)ÀÌ»ó.
  • anomalies of systemic venous return
    ´ëÁ¤¸ÆÈ¯·ù(ËÀ?ËÎÌ·Ëô)ÀÌ»ó.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anamnestic response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ(ì£ó­Øóæ¹Úãëë)
  • anaphylactic response
    ¾Æ³ªÇʶô½Ã½º ´ëÀÀ(Óßëë)
  • antibody response
    Ç×ü ´ëÀÀ(ù÷ô÷Óßëë)
  • autoimmune response
    ÀÚ°¡¸é¿ª´ëÀÀ (í»Ê«Øóæ¹Óßëë)
  • biological response modifier
    »ý¹°ÇÐÀû ´ëÀÀ¼ö½ÄÀÚ(ßæÚªùÊîÜÓßëëáóãÞí­)
  • booster response
    ºÎ½ºÅÍ ´ëÀÀ(Óßëë)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • heat shock response
    ¿­(æð)
  • immune response
    ¸é¿ª ´ëÀÀ(Øóæ¹Óßëë)
  • immune response gene
    ¸é¿ª ´ëÀÀ À¯ÀüÀÚ(Øóæ¹Óßëëë¶îîí­)
  • lysogenic response
    ¿ë¿ø´ëÀÀ(éÁê«Óßëë)
  • lytic response
    ¿ëÇØ´ëÀÀ(éÁú°Óßëë)
  • memory response
    ±â¾ï´ëÀÀ(ÑÀåãÓßëë)
  • phosphatidylinositol response
    Æ÷½ºÆÄƼµô ´ëÀÀ(Óßëë)
  • PI response
    PI ´ëÀÀ(Óßëë)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cauda equina syndrome
    ¸¶¹ÌÁõÈıº
  • cord compression syndrome
    ô¼ö¾Ð¹ÚÁõÈıº
  • Cushing's syndrome
    Äí½ÌÁõÈıº
  • double crush syndrome
    ÀÌÁߺмâÁõÈıº
  • empty sella syndrome
    °øÅÍŰ¾ÈÁõÈıº
  • facet syndrome
    ôÃßÈİüÀýÁõÈıº
  • fetal distress syndrome
    žưï¶õÁõÈıº
  • gonadal dysgenesis; Turner's syndrome
    ¼º¼±À̹߻ýÁõ, ÅͳÊÁõÈıº
  • Guillain-Barre syndrome
    ±æ¶û¹Ù·¹ÁõÈıº
  • hypogenetic lung syndrome
    Àú¹ß»ýÆóÁõÈıº
  • hypoplastic left heart syndrome
    Á½ɽÇÇü¼ººÎÀüÁõÈıº
  • idiopathic respiratory distress syndrome
    Ư¹ß¼ºÈ£Èí°ï¶õÁõÈıº
  • impingement syndrome
    Ãæµ¹ÁõÈıº
  • Klinefelter's syndrome
    Ŭ¶óÀÎÆçÅÍÁõÈıº
  • Klippel-Feil syndrome
    Ŭ¸®Æç-ÆäÀÏÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PSS painful shoulder syndrome; physiologic saline solution; porcine stress syndrome; primary Sjogren syn...
AMI Acute Myocardial Infarction
  - Complications(Cx)
    1. Early ...
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
PAIN pyoderma gangrenosum, aphthous stomatitis, inflammatory eye disease, erythema nodosum [disorders ass...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CIDP Chronic Inflammatory Demyelinating Polyneuropathy
CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy
CIBD Chronic inflammatory bowel disease
IIM Idiopathic inflammatory myopathies
IBD Inflammatory Bowel Disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • systemic related problem
    Àü½ÅÀû ¹®Á¦
  • systemic sclerosis
    Àü½Å¼º °æÈ­Áõ, °øÇÇÁõ. °æÇÇÁõ
    ÇǺÎ, ½ÉÀå, ½Äµµ, ½ÅÀå ¹× Æó¸¦ Æ÷ÇÔÇÑ ½Åü ¸ðµç ºÎÀ§ °áÇÕ Á¶Á÷ÀÇ ¸¸¼ºÀûÀÎ °æÈ­ ¹× À§Ãà. ÇǺδ ºñÈÄ, °æÈ­, °­Á÷µÇ°í Âø»öµÈ ¹ÝÀÌ »ý±ä´Ù. À̰ÍÀº Àü½Å¼ºÀÎ °æ¿ì »çÁöÀÇ ¸»´ÜºÎ³ª ¾ó±¼ ¶Ç´Â ¼Õ°¡¶ô¿¡ ±¹ÇÑµÈ °æ¿ì, EH´Â Á÷°æ ¼ö cmÀÇ l ³­Çü ¶Ç´Â ¼±»ó ¿µ¿ª¿¡ ±¹ÇÑ µÈ °æ¿ì°¡ ÀÖ´Ù.
  • systemic stage
    Àü½ÅÀûÀÎ »óÅÂ
  • systemic vasculitis
    Àü½Å¼º ¸Æ°ü¿°
  • systemic zoster
    Àü½Å¼º ´ë»ó Æ÷Áø
  • ulceration in systemic disease
    Àü½Å ÁúȯÀÇ ±Ë¾çÈ­
  • acute inflammatory demyelinating polyradiculoneuropathy
    ±Þ¼º ¿°Áõ¼º ´Ù¹ß½Å°æ¿°
    ¾ÆÁ÷µµ È®½ÇÇÏÁö ¾ÊÁö¸¸ ¸é¿ª¹ÝÀÀÀ» ÅëÇÏ¿© ³ªÅ¸³­´Ù°í ¾Ë·ÁÁ® ÀÖ´Â ½Å°æº´ÁõÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ±Þ¼ÓÈ÷ ÁøÇàÇÏ´Â ¿îµ¿½Å°æº´ÁõÀ¸·Î ÇÏÁö¿¡¼­ ½ÃÀÛÇÏ¿© »óÁö·Î ÁøÇàµÇ¸ç, Á¤µµÀÇ Â÷À̸¦ °¡Áø °¨°¢Àå¾Ö¸¦ µ¿¹ÝÇÑ´Ù.
  • anti-inflammatory
    Ç׿°Áõ¾à, Ç׿°ÁõÀÇ, Ç׿°Áõ¼ºÀÇ
    ¿°Áõ¿¡ ¹Ý´ë·Î ÀÛ¿ëÇϰųª ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â.
  • anti-inflammatory agent
    Ç׿°Áõ ¾à, ¼Ò¿°Á¦, Ç׿°ÁõÁ¦
    ¿°Áõ¿¡ ¹Ý´ë·Î ÀÛ¿ëÇϰųª ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â ¾àÁ¦.
  • chronic inflammatory trismus
    ¸¸¼º ¿°Áõ¼º ¾Æ°ü±ä±Þ
  • fibrous inflammatory hyperplasia
    ¼¶À¯ ¿°Áõ¼º °úÇü¼º
  • heavier inflammatory component
    ´õ ½ÉÇÑ ¿°Áõ ¿äÀÎ
  • inflammatory
    ¿°Áõ¼º
    ¿°Áõ°ú °ü·ÃµÈ.
  • inflammatory by-product
    ¿°Áõ ºÎ»ê¹°
  • inflammatory cell infiltration
    ¿°Áõ ¼¼Æ÷ÀÇ Ä§À±
    ¿°ÁõÀ» ÀÏÀ¸Å°¸é »ýü´Â ¹æ¾îÀûÀ¸·Î Ȱµ¿ÇÏ°í ¿°Áõ ¹°ÁúÀÇ Á¦°Å, ¿°ÁõÀÇ ÁøÀüÀ» ÀúÁöÇϱâ À§ÇØ ÁÖ·Î Ç÷¾×ÁßÀÇ ¹éÇ÷±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
systemic lupus erythematosus <immunology, nephrology, rheumatology> A disease of humans, probably autoimmune with antinuclear and other antibodies in plasma.
Immune complex deposition in the glomerular capillaries is a particular problem.
Acronym: SLE
(19 Jan 1998)
systemic mastocytosis Infiltration of many organ systems by mast cells with varied clinical manifestations that can include fever, weight loss, flushing, bronchospasm, rhinorrhoea, palpitations, dyspnea, diarrhoea, gastrointestinal bleeding, and hypotension.
Synonym: systemic mastocytosis.
(05 Mar 2000)
systemic myelitis Inflammation confined to special tracts of the spinal cord.
(05 Mar 2000)
systemic-onset juvenile chronic arthritis See: Systemic-onset juvenile rheumatoid arthritis (still's disease).
(12 Dec 1998)
systemic-onset juvenile rheumatoid arthritis <rheumatology> A form of joint disease, arthritis, that presents with systemic upset.
Clinical signs: high intermittent fever, a salmon-coloured skin rash, swollen lymph glands, enlargement of the liver and spleen, and inflammation of the lungs (pleuritis) and around the heart (pericarditis).
The arthritis itself may not be immediately apparent but once apparent, it may persist after the systemic symptoms have resolved.
Synonym: Still's disease.
(03 Jul 1999)
systemic poisoning Any disease of toxic origin.
Synonym: systemic poisoning.
Origin: toxico-+ G. -osis, condition
(05 Mar 2000)
systemic sclerosis <rheumatology> A multisystem disorder of unknown aetiology. It is characterised by fibrosis (scarring) of the skin, blood vessels and internal organs. Involvement of the gastrointestinal tract, heart, kidneys and lungs is common.
(09 Jan 1998)
systemic therapy <pharmacology> Treatment that reaches and affects cells all over the body.
(16 Dec 1997)
systemic vascular resistance An index of arteriolar compliance or constriction throughout the body; equal to the blood pressure divided by the cardiac output.
(05 Mar 2000)
systemic venous hypertension Increased pressure in the veins ultimately leading to the right atrium nearly always due to disease of the right heart but occasionally due to blockade of one or both venae cavae.
(05 Mar 2000)
juvenile chronic arthritis, systemic-onset See: Juvenile rheumatoid arthritis, systemic-onset (still's disease).
(12 Dec 1998)
juvenile rheumatoid arthritis, systemic-onset Also known as systemic-onset juvenile chronic arthritis. Still's disease presents with systemic (bodywide) illness including high intermittent fever, a salmon-coloured skin rash, swollen lymph glands, enlargement of the liver and spleen, and inflammation of the lungs (pleuritis) and around the heart (pericarditis). The arthritis may not be immediately apparent but it does always surface and it may persists long after the systemic symptoms are gone.
(12 Dec 1998)
lupus erythematosus, systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterised principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown aetiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of le cells in the blood or bone marrow.
(12 Dec 1998)
acute inflammatory polyneuropathy <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin.
The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months.
Synonym: Guillain-Barre syndrome
(12 Jul 2000)
anti-inflammatory Counteracting or suppressing inflammation.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • response
    ÀÀ´ä
  • conditioned reflex (response)
    Á¶°Ç ¹Ý»ç
  • flexible response
    ½ÅÃàÀû ´ëÀÀ(1967³â NOTO°¡ ¹Ù¸£»þ¹Ù Á¶¾à±º¿¡ ´ëÇØ¼­ äåÇÑ Àü·«)
  • flexible response
    ½ÅÃàÀû´ëÀÀ
  • frequency response
    Á֯ļöÀÀ´ä
  • galvanic skin response
    Àü±â ÇǺΠ¹ÝÀÀ(°ÅÁþ¸» ŽÁö±â¿¡ ÀÀ¿ë)
  • immune response
    ¸é¿ª ÀÀ´ä;¸é¿ª ¹ÝÀÀ
  • reader-response criticism
    µ¶ÀÚ ¹ÝÀÀÀÇ ºñÆò(reader-oriented criticismÀÇ ÀÏÁ¾)
  • response
    ÀÀ´ä;´ë´ä(answer,reply);°¨ÀÀ;¹ÝÀÀ;(ÀÚ±Ø(stimulus)¿¡ ´ëÇÑ )¹ÝÀÀ;ÀÀ´ä¹®(°¡);ÀÀâ(»çÁ¦¸¦ µû¶ó ÇÕâ´ë.½ÅµµµéÀÌ Ã¢È­ÇÏ´Â);(ºê¸®Áö¿¡¼­ÀÇ)¸®½ºÆù½º
  • response curve
    (¸¶ÀÌÅ©·ÎÆùµîÀÇ)ÀÀ´ä °î¼±
  • response time
    ÀÀ´ä ½Ã°£
  • uncondltioned response
    ¹«Á¶°Ç¹Ý»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á